BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT03131973
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
Phase 2
Completed
- Conditions
- Various Advanced Cancer
- Interventions
- Biological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 166
- Registration Number
- NCT03130959
- Locations
- 🇺🇸
Local Institution - 0046, Gainesville, Florida, United States
🇺🇸Local Institution - 0011, Chicago, Illinois, United States
🇺🇸Local Institution - 0017, New York, New York, United States
Expanded Access to Nivolumab (Opdivo)
- Conditions
- Pediatric Cancer
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03126643
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03126617
Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
Active, not recruiting
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 485
- Registration Number
- NCT03114163
- Locations
- 🇩🇪
Local Institution, Leipzig, Germany
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Cancer
- Interventions
- Biological: BMS-986218Biological: IpilimumabBiological: Nivolumab
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 512
- Registration Number
- NCT03110107
- Locations
- 🇺🇸
Local Institution - 0028, New Brunswick, New Jersey, United States
🇮🇹Local Institution - 0010, Siena, Italy
🇺🇸Local Institution - 0004, Philadelphia, Pennsylvania, United States
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- Biological: NivolumabBiological: Daratumumab
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 105
- Registration Number
- NCT03098550
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 129
- Registration Number
- NCT03090737
- Locations
- 🇿🇦
Local Institution - 0012, George, Western CAPE, South Africa
🇯🇵Local Institution - 0018, Koto-ku, Tokyo, Japan
🇯🇵Local Institution - 0023, Osaka-shi, Osaka, Japan
Treatment of Venous Thromboembolism in Real-Life Patients
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 89383
- Registration Number
- NCT03087474
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
Completed
- Conditions
- Non-Valvular Atrial Fibrillation
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 466991
- Registration Number
- NCT03087487
- Locations
- 🇺🇸
Local Institution, Ann Arbor, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath